Keyphrases
Patient Selection
100%
Patient Perspective
100%
Plaque Psoriasis
100%
Bimekizumab
100%
Interleukin-17 (IL-17)
40%
Moderate-to-severe Psoriasis
40%
Biological Treatment
30%
Psoriasis
30%
Clinical Trials
10%
Therapeutic Potential
10%
Highly Effective
10%
Therapeutic Response
10%
Monoclonal Antibody
10%
Secukinumab
10%
Adalimumab
10%
Good Safety
10%
Safety Profile
10%
Patient Well-being
10%
Patient Management
10%
Treatment Discontinuation
10%
Ustekinumab
10%
Psoriatic Arthritis
10%
Narrative Review
10%
Phase III Clinical Trial
10%
Compliance Behavior
10%
Maintenance Dose
10%
Hidradenitis Suppurativa
10%
Naïve Patients
10%
Dual Inhibition
10%
Therapeutic Perspectives
10%
Biologic-naïve
10%
Systemic Inflammatory Diseases
10%
Complete Clearance
10%
Immunology and Microbiology
Bimekizumab
100%
Interleukin 17F
20%
Interleukin 17
20%
Inflammatory Disorder
10%
Monoclonal Antibody
10%
Adalimumab
10%
Psoriatic Arthritis
10%
Ustekinumab
10%
Secukinumab
10%
Hidradenitis Suppurativa
10%
Maintenance Drug Dose
10%
Pharmacology, Toxicology and Pharmaceutical Science